CP
CPHI.US China Pharma Holdings Inc
- Market cap
- USD 22.3M
- P/E
- -
- P/B
- 0.67x
- ROE
- -14.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CPHI.US undervalued?
Graham numberThe Graham number of China Pharma Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
China Pharma Holdings Inc fundamental analysis
No fundamental analysis for China Pharma Holdings Inc yet.
China Pharma Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About China Pharma Holdings Inc
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes …
Full company profileChina Pharma Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
China Pharma Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 15.6M | 13.2M | 12.3M | 10.9M | 10.9M | 9.64M | 8.10M | 7.01M | 4.53M | 4.14M | 3.86M |
| Gross Profit | 3.22M | 2.47M | 1.97M | 1.48M | 1.95M | 349K | -494K | -281K | -1.99M | -132K | -912K |
| Operating Income | -4.19M | -4.50M | -3.97M | -3.39M | -2.58M | -2.86M | -3.55M | -2.75M | -4.59M | -3.09M | -5.10M |
| EBITDA | -4.95M | -15.3M | -7.15M | -17.5M | 107K | 230K | -838K | 8.44K | -1.96M | -1.51M | -851K |
| Net Income | -9.18M | -19.3M | -10.8M | -20.7M | -2.87M | -3.40M | -3.97M | -3.08M | -4.74M | -3.19M | -5.20M |
| EPS | -1.99 | -4.18 | -2.33 | -4.49 | -0.62 | -0.74 | -0.76 | -0.29 | -0.27 | -0.74 | -1.21 |
| Balance Sheet | |||||||||||
| Total Assets | 78.5M | 60.0M | 45.4M | 22.2M | 21.1M | 22.6M | 17.8M | 16.5M | 14.9M | 31.0M | 44.7M |
| Total Liabilities | 19.6M | 16.9M | 15.2M | 13.0M | 13.1M | 16.6M | 13.5M | 9.01M | 7.14M | 8.26M | 8.53M |
| Shareholders' Equity | 58.9M | 43.1M | 30.2M | 9.24M | 8.00M | 6.02M | 4.29M | 7.45M | 7.75M | 22.7M | 36.2M |
| Cash & Short-term Investments | 2.67M | 2.03M | 1.19M | 1.07M | 958K | 4.86M | 2.03M | 1.42M | 627K | 345K | 305K |
| Total Debt | 11.2M | 9.93M | 7.82M | 6.62M | 7.43M | 12.5M | 8.76M | 4.63M | 3.59M | 3.89M | 3.75M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.90M | 841K | 1.26M | 608K | -42.3K | -250K | -410K | -700K | -466K | 148K | -176K |
| Capital Expenditure | 193K | 136K | 51.1K | 136K | 867K | 438K | 402K | 11.5K | 292K | 137K | 11.5K |
| Free Cash Flow | 2.70M | 705K | 1.21M | 472K | -910K | -688K | -812K | -711K | -758K | 11.0K | -176K |
| Ratios | |||||||||||
| ROE | -15.6% | -44.8% | -35.6% | -224.1% | -35.8% | -56.5% | -92.6% | -41.3% | -61.1% | -14.0% | -14.4% |
| ROA | -11.7% | -32.2% | -23.7% | -93.1% | -13.6% | -15.0% | -22.3% | -18.7% | -31.8% | -10.3% | -11.6% |
| Net Profit Margin | -59.0% | -145.9% | -87.2% | -189.5% | -26.4% | -35.3% | -49.0% | -43.9% | -104.6% | -76.9% | -134.6% |
| Debt to Equity | 0.19x | 0.23x | 0.26x | 0.72x | 0.93x | 2.08x | 2.04x | 0.62x | 0.46x | 0.17x | 0.10x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
China Pharma Holdings Inc dividends
China Pharma Holdings Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Apr 15, 2025.
Who owns China Pharma Holdings Inc
- Insiders 91.72%
- Institutions 0.52%
- Public & others 7.75%
- Shares outstanding 43.0M
- Free float 3.30M
China Pharma Holdings Inc company profile
- Company name
- China Pharma Holdings Inc
- Ticker
- CPHI.US
- Exchange
- USA Stocks
- Listed since
- Apr 17, 2002
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 215
- Fiscal year end
- December
- Address
- No. 17, Jinpan Road, Haikou, China, 570216
- Phone
- 86 89 8668 11730
- Website
- chinapharmaholdings.com
About China Pharma Holdings Inc
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets, as well as Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. In addition, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.
China Pharma Holdings Inc management
2- Ms. Zhilin LiPresident, CEO, Chairman & Interim CFO · born 1953
- Ms. Huang Na C.F.A.BOD Secretary & IR Manager